AirSculpt Technologies Inc. Reports Q1 2025 Financial Results

AirSculpt Technologies, Inc., a health care company specializing in custom body contouring services, has released its financial results for the first quarter of fiscal year 2025. The company, based in Miami Beach, Florida, and listed on the Nasdaq under the ticker symbol AIRS, reported a significant decline in both revenue and case volume compared to the same period in the previous year.

For the quarter ending March 31, 2025, AirSculpt Technologies reported revenue of $39.4 million, marking a 17.3% decrease from the $47.6 million reported in the first quarter of fiscal year 2024. This decline in revenue was accompanied by a shift from profitability to a net loss. The company reported a net loss of $2.8 million for the quarter, contrasting sharply with a net income of $6 million in the same quarter of the previous year.

The financial performance for the quarter has been attributed to a decrease in case volume, which has impacted the company’s overall revenue. Analysts had anticipated these challenges, with expectations set for a quarterly loss per share of $0.035, compared to a profit of $0.100 per share in the prior year’s quarter. On the revenue side, analysts had forecasted a 17.26% decline, aligning closely with the actual reported figures.

Despite the downturn in the first quarter, AirSculpt Technologies has provided full-year guidance, although specific details were not disclosed in the recent announcements. The company continues to focus on its proprietary AirSculpt method, which offers minimally invasive body contouring services to customers across the United States.

As of April 30, 2025, AirSculpt Technologies’ stock closed at $2.26, reflecting a significant drop from its 52-week high of $9.2 on November 10, 2024. The company’s market capitalization stands at approximately $106.61 million, with a price-to-earnings ratio of -12.65, indicating the challenges it faces in returning to profitability.

Investors and stakeholders are advised to monitor the company’s progress in addressing the factors contributing to the recent financial performance, as well as any strategic initiatives aimed at reversing the downward trend in revenue and case volume. Further updates are expected as the company continues to navigate the competitive landscape of the health care sector.